Return to Results

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC

new search

Trial Conditions
  • Carcinoma, Non-Small-Cell Lung
What is the purpose of this trial?

The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
18  - 85 

Gender:
Both

Eligibility

Inclusion Criteria:

- stage IIIB or IV NSCLC

- eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab

Exclusion Criteria:

- mixed large and small cell histologies for lung cancer

- significant obesity, BMI > 30

Gender: Both
Steward Physician(s)
  • Jennifer Temel, MD
Facilities
  • St. Elizabeth's Medical Center - Completed
Trial Interventions
Drug
  • anamorelin HCl
  • anamorelin HCl
  • placebo
Physician Researcher

Investigator Name:

  • Jennifer Temel, MD

Other Information

Sponsor: Helsinn Therapeutics (U.S.), Inc
Phase: Phase 2
Trial ID: NCT00622193
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions